PwPepwise

DSIP

Sleep & Mood

a.k.a. Delta Sleep-Inducing Peptide

Nonapeptide

Delta Sleep-Inducing Peptide (DSIP) is a naturally occurring nonapeptide — a short chain of nine amino acids — found throughout the brain.

§01Summary

Delta Sleep-Inducing Peptide (DSIP) is a naturally occurring nonapeptide — a short chain of nine amino acids — found throughout the brain and body of mammals, including humans6. First isolated from the cerebral blood of sleeping rabbits in the 1970s, it was named for its ability to promote slow-wave (delta) sleep patterns in early animal experiments11. Beyond sleep, endogenous DSIP appears to play broader roles in stress hormone regulation, circadian rhythm maintenance, and neuropeptide signaling, with altered DSIP levels observed in conditions such as Alzheimer's disease8, major depression7, and Cushing syndrome16.

In early human studies, intravenous DSIP has been reported to reduce plasma ACTH levels1 and may improve objective sleep efficiency and shorten sleep onset latency in people with chronic insomnia3,20. Preliminary evidence also suggests circadian-dependent anticonvulsant activity in animal models12. However, the overall human evidence base remains in an early stage, and several indications — including its potential roles in mood disorders and neurodegeneration — are actively being investigated. The compound appears well tolerated in short-term human use at doses studied to date1,3,20, making it an interesting subject for ongoing research into sleep, neuroendocrine function, and neuropeptide-based therapeutics.

This is the layperson summary. Mechanism, dosing, the evidence base, and the published literature are in the sections below — every claim links to its source.

§02In depth

DSIP is a nonapeptide with the amino acid sequence Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu (molecular weight ~849 Da)6. Its biological activity is highly structure-dependent: only the intact nonapeptide bearing an alpha-aspartyl configuration at position 5 is active, while the beta-Asp isomer and all tested fragments (including residues 1–8, 2–9, 2–8, 1–4, and 5–9) are inactive10,11. This strict stereospecificity implies interaction with a specific receptor or recognition site, though a discrete high-affinity DSIP receptor has not been unambiguously characterized in the reviewed literature.

DSIP modulates neuroendocrine output along the hypothalamic-pituitary-adrenal (HPA) axis, with IV administration producing significant suppression of plasma ACTH-like immunoreactivity in humans without concordant changes in cortisol1 — a dissociation that may reflect effects on ACTH precursor processing or on the ratio of biologically active to immunoreactive ACTH forms. At the level of neurotransmission, adrenergic modulation has been proposed as a contributing mechanism4,6, and DSIP influences circadian rhythm parameters, consistent with its endogenous distribution pattern and the circadian dependency of several observed pharmacological effects6,12.

Blood-brain barrier (BBB) pharmacokinetics have been characterized through multiple complementary approaches with partially divergent conclusions. In-vitro BMEC monolayer studies indicate simple passive transmembrane diffusion with limited but measurable permeability comparable to water-soluble markers, and an apparent stability half-life of approximately 10 hours at the BBB interface18. In contrast, in-vivo perfusion studies in guinea pig brain identify a high-affinity saturable transport mechanism (regional Kin values 0.93–1.66 µL/min/g) with specific binding sites on brain capillary membranes17, and studies of the blood-CSF barrier demonstrate Michaelis-Menten kinetics with Kt ~5.0 nM and Vmax ~272 fmol/min19. Notably, DSIP appears to lack a specific CSF-to-blood efflux mechanism, raising the possibility of CSF accumulation following entry19. Across blood-CSF barrier experiments in dogs, CNS penetration of DSIP analogs correlated significantly with plasma concentration, plasma half-life, and lipophilicity but not with protein binding or molecular weight, with a multi-parameter model yielding r=0.813 predictive correlation13.

Electrophysiologically, DSIP produces a U-shaped dose- and infusion-time-dependent enhancement of EEG delta and spindle activity6, consistent with modulation of thalamocortical synchronization circuits underlying slow-wave sleep. Paradoxically, under isoflurane anaesthesia in humans, DSIP at 25 nmol/kg decreased delta EEG activity and increased bispectral index (lightening anaesthetic depth), also altering interhemispheric EEG symmetry2 — suggesting that DSIP's net electrophysiological effect is state-dependent and may involve interactions with GABAergic or other anaesthetic-relevant pathways. The N-terminal tryptophan residue appears important for BBB transport but not for capillary membrane binding, implying distinct molecular recognition sites for these two processes17.

§04Evidence & efficacy

Evidence base
274Studies
61Human
126Animal

DSIP has been most studied for its sleep-modulating properties. In the first reported human administration study, a single morning IV infusion of 25 nmol/kg appeared to increase total sleep time by a median of 59% within ~130 minutes and was associated with improved sleep efficiency and reduced sleep onset latency on the subsequent night20. A small controlled insomnia trial subsequently reported higher objective sleep efficiency and shorter sleep latency with DSIP compared to placebo on polysomnographic measures, though effect sizes were modest and one subjective tiredness measure improved within the DSIP group3.

In the neuroendocrine domain, IV DSIP at 25 nmol/kg appears to suppress plasma ACTH-like immunoreactivity for at least 3 hours post-injection in healthy volunteers1, though plasma and urinary cortisol levels were unaffected, suggesting a dissociation between immunoreactive ACTH and adrenocortical output at this dose1.

In animal models, DSIP has been reported to elevate pentylenetetrazol seizure thresholds during nighttime periods, suggesting time-of-day-dependent anticonvulsant activity12. Foundational preclinical work demonstrated that intact synthetic DSIP produces a statistically significant mean 35% increase in EEG delta activity in rabbits following intraventricular infusion, with strict structural specificity — no fragments or analogues reproduced this effect10,11.

As a CSF and plasma biomarker, endogenous DSIP levels have been reported to be reduced in major depression7, Alzheimer's disease8, normal-pressure hydrocephalus15, and Cushing syndrome16, and appear to normalize following effective treatment in the latter condition15, positioning DSIP as a potentially informative neuroendocrine marker across several neurological and psychiatric conditions.

§05Safety

DSIP has been administered intravenously to human volunteers and patients across several short-term studies, with no serious adverse events explicitly reported in any of the reviewed trials1,2,3,20. In the earliest human administration study (n=6), no psychological, physiological, or biochemical side effects were observed following a single 25 nmol/kg IV infusion20. A controlled insomnia study involving three consecutive nights of IV dosing similarly reported no tolerability concerns3, and the ACTH suppression RCT in healthy male volunteers documented no adverse events1.

A clinically relevant finding emerged in an anaesthesia context, where DSIP produced cardiovascular effects including increased heart rate and decreased heart rate variability, indicating reduced parasympathetic tone2. Additionally, in that same study, DSIP paradoxically lightened anaesthetic depth rather than deepening it at the doses tested2, representing an unexpected pharmacodynamic interaction with volatile anaesthetic agents that warrants consideration in perioperative settings.

In animal models, DSIP administration during daytime hours appeared to increase seizure vulnerability relative to saline controls, with protective anticonvulsant effects observed only during nighttime periods12. This circadian dependency of effect direction suggests that timing of administration may be pharmacologically meaningful.

Long-term safety data and repeat-dosing tolerability profiles are areas where the human evidence base is actively developing. Studies to date have been limited to single doses or short multi-day protocols in small cohorts.

§06History

DSIP was first isolated in 1974–1977 by Georges Schoenenberger and Marcel Monnier at the University of Basel, extracted from the cerebral venous blood dialysate of rabbits subjected to hypnogenic thalamic stimulation during sleep11. The peptide was named for its capacity to induce delta EEG patterns — the slow oscillations characteristic of deep, restorative sleep — when infused intraventricularly into recipient rabbits. Its complete amino acid sequence (Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu) and synthetic recapitulation of biological activity were established in 1977–197810,11, making DSIP one of the early characterized endogenous sleep-regulatory peptides.

Throughout the 1980s, research expanded rapidly: Graf and Kastin published influential reviews in 1984 and 1986 cataloguing DSIP's diverse effects across sleep, hormonal regulation, circadian biology, pain, and withdrawal syndromes6,4. Early human administration studies appeared in the early 1980s20, and by the late 1980s controlled trials were examining its neuroendocrine and sleep effects1,3. Immunohistochemical and radioimmunochemical mapping established widespread DSIP-like immunoreactivity throughout the brain and peripheral organs4,6, and pharmacokinetic studies across the same decade characterized its BBB and blood-CSF barrier transport properties9,13,17,18,19.

During the 1990s, interest shifted partly toward DSIP as a CSF and plasma biomarker, with reduced endogenous levels documented in Alzheimer's disease8, major depression7, normal-pressure hydrocephalus15, and Cushing syndrome16. No regulatory approvals have been reported. The compound continues to be an active subject of mechanistic and translational research, with its neuroendocrine and sleep-regulatory roles informing broader investigation of endogenous peptide therapeutics.

§07References